{"preliminary_commentary":{"by_channel":{"podcast":7,"x_thread":5,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06765109\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ALKAZAR","nct_id":"NCT06765109","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alkazar-nct06765109. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ALKAZAR","arms":[{"description":"150mg taken orally once daily (QD)","label":"Neladalkib (NVL-655)","type":"EXPERIMENTAL"},{"description":"600mg taken orally twice daily (BID)","label":"Alectinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-12","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer","Anaplastic Lymphoma Kinase-positive"],"enrollment":{"count":450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Neladalkib (NVL-655)","otherNames":[],"type":"DRUG"},{"name":"Alectinib","otherNames":["Alecensa"],"type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"Nuvalent Inc.","official_title":"A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) per blinded independent central review (BICR)","timeFrame":"Up to 5 years after first patient dosed"}],"references":[],"start_date":{"date":"2025-07-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","url":"https://clinicaltrials.gov/study/NCT06765109"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alkazar-nct06765109"}